Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adverse effect are lacking. We will evaluate changes of lens transparency after administration of systemic corticosteroid therapy for at least one year with Scheimpflug photography and quantification of lens autofluorescence.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Treatments: Prednisolone

Criteria

Inclusion Criteria:

• Patient who starts a treatment with Prednisone, Prednisolone or Methylprednisolone for an Expected time of one year at least, with normal lens autofluorescence at inclusion.

Exclusion Criteria:

• Previous cataracts and abnormal increase of lens autofluorescence considering age

• Previous elevation of intraocular pressure

• Progressive inflammatory or non inflammatory ocular disease

• Eye drop except artificial tears

• Insulin dependent and non insulin dependent diabetes

• Atopic dermatitis

• Previous protracted corticosteroid therapy

• Drugs known to be associated with an increased risk of cataract